[131I]FIAU labeling of genetically transduced, tumor-reactive lymphocytes: cell-level dosimetry and dose-dependent toxicity
- First Online:
- 140 Downloads
Donor T cells have been shown to be reactive against and effective in adoptive immunotherapy of Epstein-Barr virus (EBV) lymphomas which develop in some leukemia patients post marrow transplantation. These T cells may be genetically modified by incorporation of a replication-incompetent viral vector (NIT) encoding both an inactive mutant nerve growth factor receptor (LNGFR), as an immunoselectable surface marker, and a herpes simplex virus thymidine kinase (HSV-TK), rendering the cells sensitive to ganciclovir. The current studies are based on the selective HSV-TK-catalyzed trapping (phosphorylation) of the thymidine analog [131I]-2′-fluoro-2′-deoxy-1-β-D-arabinofuransyl-5-iodo-uracil (FIAU) as a means of stably labeling such T cells for in vivo trafficking (including tumor targeting) studies. Because of the radiosensitivity of lymphocytes and the potentially high absorbed dose to the nucleus from intracellular 131I (even at tracer levels), the nucleus absorbed dose (Dn) and dose-dependent immune functionality were evaluated for NIT+ T cells labeled ex vivo in [131I]FIAU-containing medium.
Based on in vitro kinetic studies of [131I]FIAU uptake by NIT+ T cells, Dn was calculated using an adaptation of the MIRD formalism and the recently published MIRD cellular S factors. Immune cytotoxicity of [131I]FIAU-labeled cells was assayed against 51Cr-labeled target cells [B-lymphoblastoid cells (BLCLs)] in a standard 4-h release assay.
Results and conclusion
At median nuclear absorbed doses up to 830 cGy, a 51Cr-release assay against BLCLs showed no loss of immune cytotoxicity, thus demonstrating the functional integrity of genetically transduced, tumor-reactive T cells labeled at this dose level for in vivo cell trafficking and tumor targeting studies.
KeywordsMolecular imaging Radiobiology/dosimetry Radiopharmaceuticals Cell labeling Cell trafficking
- 8.Drobyski WR, Keever CA, Roth MS, Koethe S, Hanson G, McFadden P, et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 1993;82:2310–2318PubMedGoogle Scholar
- 9.Mackinnon S, Papadopoulos EB, Carabasi MH, Reich L, Collins NH, Boulad F, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995;86:1261–1268PubMedGoogle Scholar
- 16.Koehne G, Smith KM, Ferguson TL, Williams RY, Heller G, Pamer EG, et al. Quantitation, selection, and functional characterization of Epstein-Barr virus-specific and alloreactive T cells detected by intracellular interferon-gamma production and growth of cytotoxic precursors. Blood 2002;99:1730–1740CrossRefPubMedGoogle Scholar
- 17.Goddu SM, Howell RW, Bouchet LG, Bolch WE, Rao DV. MIRD cellular S factors: self-absorbed dose per unit cumulated activity for selected radionuclides and monoenergetic electron and alpha particle emitters incorporated into different cell compartments. Reston, VA: Society of Nuclear Medicine; 1997Google Scholar
- 18.Weber D, Eckerman K, Dillman L, Ryman J. MIRD: radionuclide data and decay schemes. New York: Society of Nuclear Medicine; 1989Google Scholar
- 21.Coleman R, Datz F. Detection of inflammatory disease using radiolabeled cells. In: Sandler M, Patton J, Coleman R, et al., editors. Diagnostic nuclear medicine. Baltimore, MD: Williams & Wilkins; 1996; pp. 1509–1524Google Scholar
- 22.Harwood SJ, Camblin JG, Hakki S, Morrissey MA, Laven DL, Zangara LM, et al. Use of technetium antigranulocyte monoclonal antibody Fab’ fragments for the detection of osteomyelitis. Cell Biophys 1994;25:99–107Google Scholar
- 31.Nishimura Y, Nakamura H. Radioactive iodination of lymphocyte surface proteins and characterization of their molecular properties. J Biochem (Tokyo) 1982;91:1679–1686Google Scholar